• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

作者信息

Mulligan Mark J, Lyke Kirsten E, Kitchin Nicholas, Absalon Judith, Gurtman Alejandra, Lockhart Stephen, Neuzil Kathleen, Raabe Vanessa, Bailey Ruth, Swanson Kena A, Li Ping, Koury Kenneth, Kalina Warren, Cooper David, Fontes-Garfias Camila, Shi Pei-Yong, Türeci Özlem, Tompkins Kristin R, Walsh Edward E, Frenck Robert, Falsey Ann R, Dormitzer Philip R, Gruber William C, Şahin Uğur, Jansen Kathrin U

机构信息

New York University Langone Vaccine Center, New York, NY, USA.

New York University Grossman School of Medicine, New York, NY, USA.

出版信息

Nature. 2021 Feb;590(7844):E26. doi: 10.1038/s41586-020-03098-3.

DOI:10.1038/s41586-020-03098-3
PMID:33469216
Abstract
摘要

相似文献

1
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.出版商更正：COVID-19 RNA疫苗BNT162b1在成人中的I/II期研究。
Nature. 2021 Feb;590(7844):E26. doi: 10.1038/s41586-020-03098-3.
2
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.出版商更正：新冠病毒疫苗BNT162b1引发人体抗体和T1 T细胞反应。
Nature. 2021 Feb;590(7844):E17. doi: 10.1038/s41586-020-03102-w.
3
Publisher Correction: An immunological autobiography: my year as a COVID-19 vaccine trial participant.出版商更正：一份免疫学自传：我作为新冠疫苗试验参与者的一年。
NPJ Vaccines. 2022 Aug 19;7(1):97. doi: 10.1038/s41541-022-00522-9.
4
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial.出版商更正：PREVENT-19新冠疫苗效力临床试验的免疫相关分析
Nat Commun. 2023 Mar 22;14(1):1581. doi: 10.1038/s41467-023-37367-2.
5
Publisher Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.出版商更正：2019冠状病毒病大流行期间的乳腺癌管理路径：英国B-MaP-C研究“4级警戒”阶段的结果。
Br J Cancer. 2021 Sep;125(6):905. doi: 10.1038/s41416-021-01465-z.
6
COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.COVID-19 疫苗：现状及在印度尼西亚使用的意义。
Acta Med Indones. 2020 Oct;52(4):388-412.
7
Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.出版商更正：一种用于测试COVID-19应对措施的新冠病毒小鼠适应模型。
Nature. 2021 Feb;590(7844):E22. doi: 10.1038/s41586-020-03107-5.
8
Publisher Correction: Estimating and explaining the spread of COVID-19 at the county level in the USA.出版商更正：美国县级新冠病毒病（COVID-19）传播情况的估计与解释
Commun Biol. 2021 Jan 20;4(1):115. doi: 10.1038/s42003-021-01679-0.
9
Publisher Correction: Risk factors for death from COVID-19.出版商更正：2019冠状病毒病死亡的风险因素。
Nat Rev Immunol. 2020 Jul;20(7):448. doi: 10.1038/s41577-020-0371-9.
10
Publisher Correction: COVID-19 antibodies on trial.出版商更正：新冠病毒抗体试验。
Nat Biotechnol. 2021 Feb;39(2):246. doi: 10.1038/s41587-021-00813-x.

引用本文的文献

1
Safety monitoring of precautionary third dose of COVID-19 vaccines in a district in Northern India.印度北部某地区新冠疫苗第三剂预防接种的安全性监测
J Family Med Prim Care. 2024 May;13(5):1875-1880. doi: 10.4103/jfmpc.jfmpc_973_23. Epub 2024 May 24.
2
Circular RNA: A promising new star of vaccine.环状RNA：疫苗领域一颗冉冉升起的新星。
J Transl Int Med. 2023 Dec 20;11(4):372-381. doi: 10.2478/jtim-2023-0122. eCollection 2023 Dec.
3
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
在 18 岁及以上中国参与者中进行的一种新型冠状病毒 2 型 mRNA 疫苗（SYS6006）的基础免疫接种的安全性和免疫原性：两项随机、观察者设盲、安慰剂对照和剂量递增的 1 期临床试验。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18.
4
Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran.伊朗舒什塔尔医护人员中冠状病毒疫苗的副作用比较
Clin Pathol. 2023 Apr 19;16:2632010X231166798. doi: 10.1177/2632010X231166798. eCollection 2023 Jan-Dec.
5
Levels of SARS-COV-2 anti-spike protein receptor-binding domain (S-RBD) IgG in Indonesian-vaccinated healthcare workers: experimental research.印度尼西亚接种疫苗的医护人员中SARS-CoV-2抗刺突蛋白受体结合域（S-RBD）IgG水平：实验研究
Ann Med Surg (Lond). 2023 Apr 4;85(4):802-806. doi: 10.1097/MS9.0000000000000425. eCollection 2023 Apr.
6
HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的HLA-I和HLA-II肽组：综述
Vaccines (Basel). 2023 Feb 25;11(3):548. doi: 10.3390/vaccines11030548.
7
Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review.基于 siRNA 的非病毒载体的研究现状与展望：综述。
Int J Mol Sci. 2023 Feb 8;24(4):3375. doi: 10.3390/ijms24043375.
8
Delta Variant: Partially Sensitive To Vaccination, but Still Worth Global Attention.德尔塔变种：对疫苗部分敏感，但仍值得全球关注。
J Transl Int Med. 2022 Sep 24;10(3):227-235. doi: 10.2478/jtim-2022-0026. eCollection 2022 Sep.
9
A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.沙特阿拉伯东部省女性中辉瑞-生物科技/BNT162b2 COVID-19 疫苗加强针相关副作用的回顾性评估。
Vaccine. 2022 Nov 22;40(49):7087-7096. doi: 10.1016/j.vaccine.2022.10.009. Epub 2022 Oct 17.
10
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.针对新冠病毒变异株的二价mRNA疫苗的研发
Vaccines (Basel). 2022 Oct 26;10(11):1807. doi: 10.3390/vaccines10111807.